Beyond the established benefits of GLP‐1 receptor activation on weight loss, whole body insulin sensitivity, and hepatic steatosis, and possibly fibroinflammation, GIP receptor agonism has been shown to exert complementary metabolic effects, including enhanced lipid handling, adipose tissue remodelling, and improved insulin action. This evidence concerns the gene INS and fatty liver disease.